Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

On July 6, 2026, Fate Therapeutics, Inc. shared that they will present initial clinical findings on their off-the-shelf CAR T-cell product, FT819, at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting in Montréal, Canada from July 8 to 11, 2026. Fate Therapeutics is a clinical-stage biopharmaceutical corporation listed on the NASDAQ as FATE. The company focuses on delivering a revolutionary array of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to cancer and autoimmune disease patients. This event will showcase important updates on their product aimed at benefiting a large patient population.